id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1977-N-0023-0005,FDA,FDA-1977-N-0023,"Reference 5 : Verheugt, F. W. et al., ""Effects of Early Intervention with Low Dose Aspirin (100 mg) on Infarct Size, Reinfarction and Mortality in Anterior Wall Acute Myocardial Infarction,"" American Journal of Cardiology, 66:267-270, 1990 re: Background Material from FDA",Supporting & Related Material,Background Material,2003-06-17T04:00:00Z,2003,6,,,2019-02-12T17:08:47Z,,0,0,09000064805da1f0
FDA-1977-N-0023-0008,FDA,FDA-1977-N-0023,"Reference 9 : Husted, S. E. et al., ""Acetylsalicylic Acid 100 mg and 1,000 mg Daily in Acute Myocardial Infarction Suspects: A Placebo-Controlled Trial,"" Journal of Internal Medicine, 226:303-310, 1989 re: Background Material from FDA",Supporting & Related Material,Background Material,2003-06-17T04:00:00Z,2003,6,,,2019-02-12T17:34:26Z,,0,0,09000064805da1f3
FDA-1977-N-0023-0006,FDA,FDA-1977-N-0023,"Reference 6 : Hays, L. J. et al., ""Short-term Infarct Vessel Patency with Aspirin and Dipyridamole Started 24 to 36 Hours after Intravenous Streptokinase,"" American Heart Journal, 115:717-721, 1988. re: Background Material from FDA",Supporting & Related Material,Background Material,2003-06-17T04:00:00Z,2003,6,,,2019-02-12T17:15:00Z,,0,0,09000064805da1f1
FDA-1977-N-0023-0010,FDA,FDA-1977-N-0023,Background Material from FDA,Supporting & Related Material,Background Material,2003-06-17T04:00:00Z,2003,6,,,2019-02-13T19:04:25Z,,0,0,09000064805da1f5
FDA-1977-N-0023-0009,FDA,FDA-1977-N-0023,Tab 1.2 - Correspondence re: Background Material from FDA,Supporting & Related Material,Background Material,2003-06-17T04:00:00Z,2003,6,,,2019-02-12T18:52:35Z,,0,0,09000064805da1f4
FDA-1977-N-0023-0012,FDA,FDA-1977-N-0023,"Reference 7 : ISIS Pilot Study Investigators, ""Randomized Factorial Trial of High-Dose Intravenous Streptokinase, of Oral Aspirin and of Intravenous Heparin in Acute Myocardial Infarction,"" European Heart Journal 8:634-642, 1987 re: Background Material from FDA",Supporting & Related Material,Background Material,2003-06-17T04:00:00Z,2003,6,,,2019-02-12T17:21:23Z,,0,0,09000064805da1f7
FDA-1977-N-0023-0004,FDA,FDA-1977-N-0023,"Reference 4 : RISC Group, ""Risk of Myocardial Infarction and Death During Treatment with Low Dose Aspirin and Intravenous Heparin in Men with Unstable Coronary Artery Disease,"" Lancet, 336:827-830, 1990 re: Background Material from FDA",Supporting & Related Material,Background Material,2003-06-17T04:00:00Z,2003,6,,,2019-02-13T19:06:47Z,,0,0,09000064805da1ef
FDA-1977-N-0023-0003,FDA,FDA-1977-N-0023,"Reference 3 : ISIS-2 (Second International Study of Infarct Survival) Collaborative Group, ""Randomized Trial of Intravenous Streptokinase, Oral Aspirin, Both, or Neither Among 17,187 Cases of Suspected
Acute Myocardial Infarction: ISIS-2,"" Lancet, 2:349-360, 1988. re: Background Material from FDA",Supporting & Related Material,Background Material,2003-06-17T04:00:00Z,2003,6,,,2019-02-13T19:06:14Z,,0,0,09000064805da1ee
FDA-1977-N-0023-0011,FDA,FDA-1977-N-0023,Tab 1.1 - References (3 through 9) re: Background Material from FDA,Supporting & Related Material,Background Material,2003-06-17T04:00:00Z,2003,6,,,2019-02-13T19:05:34Z,,0,0,09000064805da1f6
FDA-1977-N-0023-0007,FDA,FDA-1977-N-0023,"Reference 8 : Elwood, P. C., and W. 0. Williams, ""A Randomized Controlled Trial of Aspirin in the Prevention of Early Mortality in Myocardial Infarction,"" Journal of the Royal College of General Practitioners, 29:413-416, 1979. re: Background Material from FDA",Supporting & Related Material,Background Material,2003-06-17T04:00:00Z,2003,6,,,2019-02-12T17:30:23Z,,0,0,09000064805da1f2
FDA-1977-N-0023-0002,FDA,FDA-1977-N-0023,"Internal Memorandum from Valerie J. Miguele (HFD-560) to FDA DDM (HFA-305) June 17, 1996",Other,Memorandum,1996-07-02T04:00:00Z,1996,7,,,2019-02-13T14:22:59Z,,0,0,09000064805da1b5
FDA-1977-N-0023-0001,FDA,FDA-1977-N-0023,"Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use; Proposed Amendment to the Tentative Final Monograph",Proposed Rule,Notice of Proposed Rulemaking (NPRM),1996-06-25T04:00:00Z,1996,6,1996-06-25T04:00:00Z,1996-09-12T03:59:59Z,2019-03-23T23:59:37Z,96-14894,0,0,09000064805da1b4